A. Schapira

发表

Deficit of in vivo mitochondrial ATP production in patients with Friedreich ataxia.

D. Manners, P. Styles, R. Lodi, 1999, Proceedings of the National Academy of Sciences of the United States of America.

Compensatory mechanisms in Parkinson's disease

J. Obeso, A. Schapira, A. Schapira, 2010 .

Missing pieces in the Parkinson's disease puzzle

M. Farrer, E. Hirsch, J. Obeso, 2010, Nature Medicine.

Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities

W. Oertel, W. Poewe, J. Obeso, 2013, The Lancet Neurology.

The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire

K. Chaudhuri, W. Ondo, P. Martínez-Martín, 2010, Movement disorders : official journal of the Movement Disorder Society.

Non-motor features of Parkinson disease

K. Chaudhuri, A. Schapira, A. Schapira, 2017, Nature Reviews Neuroscience.

Priorities in Parkinson's disease research

Paola Piccini, Thomas Gasser, Erwan Bezard, 2011, Nature Reviews Drug Discovery.

The relationship between glucocerebrosidase mutations and Parkinson disease

A. Schapira, A. Migdalska‐Richards, Anna Migdalska‐Richards, 2016, Journal of neurochemistry.

Complex I, Iron, and ferritin in Parkinson's disease substantia nigra

C. Marsden, J. Cooper, A. Schapira, 1994, Annals of neurology.

Non-motor features of Parkinson disease

K. Ray Chaudhuri, K. Chaudhuri, A. Schapira, 2017, Nature Reviews Neuroscience.

Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing

A. Schapira, J. Holton, H. Houlden, 2019, Acta Neuropathologica Communications.

Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease

Murat Emre, Werner Poewe, Karl Kieburtz, 2013, Movement disorders : official journal of the Movement Disorder Society.

Neuronal death and Parkinson's disease

J. Obeso, A. Schapira, W. Olanow, 1999 .

Polyglutamine expansions cause decreased CRE-mediated transcription and early gene expression changes prior to cell death in an inducible cell model of Huntington's disease.

D. Rubinsztein, A. Schapira, J. Swartz, 2001, Human molecular genetics.

The PINK1 – Parkin mitophagy signalling pathway is not functional in peripheral blood mononuclear cells

A. Schapira, H. Morris, J. Taanman, 2020, bioRxiv.

Expression of mutant α-synuclein causes increased susceptibility to dopamine toxicity

Sarah J. Tabrizi, Jan-Willem Taanman, Thomas T. Warner, 2000 .

Rasagiline protects against alpha-synuclein induced sensitivity to oxidative stress in dopaminergic cells

J. Cooper, A. Schapira, K. Chau, 2010, Neurochemistry International.

The use of rasagiline in Parkinson's disease.

A. Schapira, 2006, Journal of neural transmission. Supplementum.

Recharging mitochondrial batteries in old eyes. Near infra-red increases ATP.

T. Salt, A. Schapira, G. Jeffery, 2014, Experimental eye research.

Long‐term efficacy and safety of safinamide as add‐on therapy in early Parkinson's disease

M. Onofrj, A. Schapira, A. Schapira, 2013, European journal of neurology.

Neuroprotection for Parkinson's disease: Prospects and promises

Y. Agid, C. Olanow, A. Schapira, 2003, Annals of neurology.

Irreversible Inhibition of Mitochondrial Complex I by 1‐Methyl‐4‐Phenylpyridinium: Evidence for Free Radical Involvement

J. Cooper, A. Schapira, A. Schapira, 1992, Journal of neurochemistry.

Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats

J. Obeso, G. Mengod, A. Schapira, 2014, Neurobiology of Disease.

The clinical relevance of levodopa toxicity in the treatment of Parkinson's disease

A. Schapira, A. Schapira, 2008, Movement disorders : official journal of the Movement Disorder Society.

Continuous subcutaneous infusion of pramipexole protects against lipopolysaccharide-induced dopaminergic cell death without affecting the inflammatory response

A. Schapira, P. Jenner, M. Sadeghian, 2008, Experimental Neurology.

Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity

S. Tabrizi, A. Schapira, M. Orth, 2000, Neurology.

Mitochondrial function in Parkinson's disease

C. Marsden, J. Cooper, A. Schapira, 1992 .

Clinical prodromes of neurodegeneration in Anderson-Fabry disease

Atul Mehta, Matthias Löhle, Heinz Reichmann, 2015, Neurology.

Glucocerebrosidase in the pathogenesis and treatment of Parkinson disease

A. Schapira, M. Gegg, Matthew E Gegg, 2013, Proceedings of the National Academy of Sciences.

Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease

B. Summers, P. Leigh, A. Schapira, 1992, The Lancet.

Platelet mitochondrial function in Parkinson's disease. The Royal Kings and Queens Parkinson Disease Research Group.

C. Marsden, J. Cooper, A. Schapira, 1992, Annals of neurology.

A comparison of lorazepam and diazepam as initial therapy in convulsive status epilepticus.

A. Schapira, Hannah R Cock, 2002, QJM : monthly journal of the Association of Physicians.

Extended-release pramipexole in early Parkinson disease

W. Poewe, O. Rascol, R. Hauser, 2011, Neurology.

The importance of LRRK2 mutations in Parkinson disease.

A. Schapira, 2006, Archives of neurology.

Timing the initiation of treatment in Parkinson’s disease

A. Schapira, D. Grosset, 2007, Journal of Neurology, Neurosurgery, and Psychiatry.

Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease

J. Cooper, A. Schapira, A. Schapira, 1993, Brain Research.

A LON-ClpP Proteolytic Axis Degrades Complex I to Extinguish ROS Production in Depolarized Mitochondria

A. Schapira, J. Taanman, Kenneth R. Pryde, 2016, Cell reports.

Severe impairment of complex I-driven adenosine triphosphate synthesis in leber hereditary optic neuropathy cybrids.

A. Schapira, A. Martinuzzi, A. Baruzzi, 2005, Archives of neurology.

Etiology and pathogenesis of Parkinson's disease

A. Schapira, P. Jenner, 2011, Movement disorders : official journal of the Movement Disorder Society.

A clinical, genetic and biochemical study of SPG7 mutations in hereditary spastic paraplegia.

N. Wood, A. Schapira, A. Crosby, 2004, Brain : a journal of neurology.

A clinical , genetic and biochemical study of SPG 7 mutations in hereditary spastic paraplegia

N. Wood, A. Schapira, A. Crosby, 2022 .

High-dose creatine therapy for Huntington disease: A 2-year clinical and MRS study

A. Blamire, S. Tabrizi, D. Manners, 2005, Neurology.

A 31P magnetic resonance spectroscopy study of mitochondrial function in skeletal muscle of patients with Parkinson's disease

C. Marsden, G. Kemp, J. Cooper, 1994, Journal of the Neurological Sciences.

Mitochondrial function and parental sex effect in Huntington's disease

Y. Agid, J. Cooper, A. Schapira, 1990, The Lancet.

A new family with paroxysmal exercise induced dystonia and migraine: a clinical and genetic study

N. Quinn, K. Bhatia, N. Wood, 2000, Journal of neurology, neurosurgery, and psychiatry.

Paraneoplastic “stiff person syndrome” with metastatic adenocarcinoma and anti-Ri antibodies

A. Leff, A. Schapira, N. Turner, 2004, Neurology.

Advances in the Understanding of the Cause of Parkinson's Disease

A. Schapira, A. Schapira, 1994, Journal of the Royal Society of Medicine.

Mitochondrial Respiratory Chain Dysfunction in Ageing; Influence of Vitamin E Deficiency

J. Cooper, A. Schapira, R. Rafique, 2004, Free radical research.

Mitochondrial DNA in focal dystonia: A cybrid analysis

S. Tabrizi, J. Cooper, A. Schapira, 1998, Annals of neurology.

Mitochondrial respiratory chain function in multiple system atrophy

C. Marsden, N. Quinn, J. Cooper, 1997, Movement disorders : official journal of the Movement Disorder Society.

L‐Dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain

C. Marsden, J. Cooper, A. Schapira, 1995, Movement disorders : official journal of the Movement Disorder Society.

Platelet mitochondrial function in Leber's hereditary optic neuropathy

J. Cooper, A. Schapira, A. Harding, 1994, Journal of the Neurological Sciences.

Expression of mutant alpha-synuclein causes increased susceptibility to dopamine toxicity.

S. Tabrizi, J. Cooper, A. Schapira, 2000, Human molecular genetics.

Minimal Clinically Important Difference in Parkinson's Disease as Assessed in Pivotal Trials of Pramipexole Extended Release

W. Poewe, O. Rascol, R. Hauser, 2014, Parkinson's disease.

End-of-dose Wearing Off in Parkinson Disease: A 9-Question Survey Assessment

E. Tolosa, W. Oertel, M. Stacy, 2006, Clinical neuropharmacology.

Ropinirole monotherapy induced severe reversible dyskinesias in Parkinson's disease

A. Batla, M. Stamelou, K. Bhatia, 2013, Movement disorders : official journal of the Movement Disorder Society.

Prodest - Depressive symptoms in Parkinson's disease: Demographic data

Paolo Barone, Paolo Barone, Anthony H.V. Schapira, 2007 .

Mitochondrial and lysosomal biogenesis are activated following PINK1/parkin‐mediated mitophagy

A. Schapira, K. Chau, M. Gegg, 2015, Journal of neurochemistry.

Detection of nitrosyl complexes in human substantia nigra, in relation to Parkinson's disease.

C. Cooper, J. Cooper, A. Schapira, 1996, Biochemical and biophysical research communications.

P1.203 Immediate vs. delayed-start pramipexole in early Parkinson's disease: the PROUD study

W. Poewe, O. Rascol, M. Mcdermott, 2009 .

Creatine therapy for Huntington’s disease: Clinical and MRS findings in a 1-year pilot study

A. Blamire, D. Manners, P. Styles, 2003, Neurology.

Pathogenetic insights into young-onset Parkinson disease

A. Schapira, H. Morris, 2020, Nature Reviews Neurology.

Parkinsonism in patients with chronic hepatitis C treated with interferon-alpha2b: a report of two cases.

A. Schapira, M. Morgan, P. Amodio, 2010, European journal of gastroenterology & hepatology.

Creation of an Open-Access, Mutation-Defined Fibroblast Resource for Neurological Disease Research

Martin N. Rossor, Margaret Sutherland, Colin J. Mahoney, 2012, PloS one.

Mitochondrial myopathy with a defect of mitochondrial-protein transport.

J. Cooper, A. Schapira, A. Schapira, 1990, The New England journal of medicine.

First-line First-line treatment in treatment in Parkinson's Parkinson's disease disease

C. Davie, A. Schapira, 2005 .

Glucocerebrosidase deficiency promotes release of α-synuclein fibrils from cultured neurons

A. Schapira, M. Gegg, Matthew E Gegg, 2020, Human molecular genetics.

Pathogenic Parkinson’s disease mutations across the functional domains of LRRK2 alter the autophagic/lysosomal response to starvation☆

Michael J. Devine, J. Hardy, A. Schapira, 2013, Biochemical and biophysical research communications.

The molecular pathology of human respiratory chain defects.

J. Cooper, A. Schapira, A. Harding, 1991, Revue neurologique.

Clinical, biochemical and molecular genetic features of Leber's hereditary optic neuropathy.

A. Schapira, A. Schapira, R. Chalmers, 1999, Biochimica et biophysica acta.

The influence of nuclear background on the biochemical expression of 3460 Leber's hereditary optic neuropathy

S. Tabrizi, J. Cooper, A. Schapira, 1998, Annals of neurology.

Mitochondrial function in Alzheimer's disease

J. Cooper, A. Schapira, A. Schapira, 1993, The Lancet.

Can we improve the holistic assessment of Parkinson's disease? The development of a non-motor symptom questionnaire and scale for Parkinson's disease.

K. Chaudhuri, W. Koller, A. Schapira, 2004 .

The mitochondrial myopathies. Defects of the mitochondrial respiratory chain and oxidative phosphorylation system.

D. J. Hayes, J. Cooper, A. Schapira, 1987, Electroencephalography and clinical neurophysiology. Supplement.

Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage

M. Duchen, N. Wood, A. Schapira, 2013, Neurochemistry International.

Movement disorders 4

A. Lang, S. Fahn, A. Schapira, 2010 .

Mitochondria and Control Defects in a Mouse Model of Gaucher Disease-Links to Parkinson's Disease

M. Duchen, A. Schapira, S. Brandner, 2020 .

Glucocerebrosidase mutations and Parkinson disease

A. Schapira, S. R. Vieira, Sophia R. L. Vieira, 2022, Journal of Neural Transmission.

Leber hereditary optic neuropathy mtDNA mutations disrupt glutamate transport in cybrid cell lines.

A. Schapira, A. Martinuzzi, V. Carelli, 2004, Brain : a journal of neurology.

Oxidative Stress and Parkinson's Disease a

C. Marsden, A. Schapira, A. Schapira, 1996, Annals of the New York Academy of Sciences.

Mitochondrial function in Huntington's disease: Clues for pathogenesis and prospects for treatment

A. Schapira, 1997, Annals of neurology.

Glucocerebrosidase activity, cathepsin D and monomeric α-synuclein interactions in a stem cell derived neuronal model of a PD associated GBA1 mutation

A. Schapira, M. Gegg, D. Chau, 2020, Neurobiology of Disease.

In vivo skeletal muscle mitochondrial function in Leber's hereditary optic neuropathy assessed by 31P magnetic resonance spectroscopy

G. Radda, S. Tabrizi, P. Styles, 1997, Annals of neurology.

Polypeptide and glycoprotein abnormalities in dorsal root ganglia of streptozotocin-diabetic rats

A. Schapira, P. Thomas, A. Schapira, 1989, Journal of the Neurological Sciences.

CAV3 mutations causing exercise intolerance, myalgia and rhabdomyolysis: Expanding the phenotypic spectrum of caveolinopathies

A. Schapira, G. Ravenscroft, N. Laing, 2016, Neuromuscular Disorders.

Mitochondrial DNA in idiopathic cardiomyopathy.

J. Cooper, A. Schapira, S. Kaddoura, 1998, European heart journal.

Mitochondrial DNA (mtDNA) diseases: correlation of genotype to phenotype.

J. Cooper, A. Schapira, A. Harding, 1995, Biochimica et biophysica acta.

GBA mutation promotes early mitochondrial dysfunction in 3D neurosphere models

E. Tolosa, A. Schapira, M. Marti, 2019, Aging.

Human mitochondrial complex I dysfunction.

J. Cooper, A. Schapira, D. Krige, 1992, Biochimica et biophysica acta.

Sensitivity of respiratory chain activities to lipid peroxidation: effect of vitamin E deficiency.

J. Cooper, A. Schapira, R. Rafique, 2001, The Biochemical journal.

A case of mitochondrial myopathy, lactic acidosis and complex I deficiency

N. Bresolin, P. Cerretelli, T. Binzoni, 1990, Journal of Neurology.

The molecular pathology of respiratory-chain dysfunction in human mitochondrial myopathies.

J. Cooper, A. Schapira, A. Harding, 1990, Biochimica et biophysica acta.

Functional consequences of the 3460-bp mitochondrial DNA mutation associated with Leber’s hereditary optic neuropathy

J. Cooper, A. Schapira, Hannah R Cock, 1999, Journal of the Neurological Sciences.

The 14484 ND6 mtDNA mutation in Leber hereditary optic neuropathy does not affect fibroblast complex I activity.

J. Cooper, A. Schapira, Hannah R Cock, 1995, American journal of human genetics.

Painful third nerve palsy in MS.

A. Schapira, P. Bentley, T. Kimber, 2002, Neurology.

Immunological Phenotyping of Fibroblast Cultures from Patients with a Mitochondrial Respiratory Chain Deficit

A. Schapira, J. Leonard, J. Taanman, 2001, Laboratory Investigation.

Erratum: Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease (The Lancet, vol. 339/8806 (1375-1377))

P. Leigh, A. Schapira, A. Harding, 1992 .

Mitochondrial DNA depletion syndrome is expressed in amniotic fluid cell cultures.

J. Cooper, A. Schapira, J. Taanman, 1999, The American journal of pathology.

Novel pharmacological targets for the treatment of Parkinson's disease

Erwan Bezard, Bastian Hengerer, G. Collingridge, 2006, Nature Reviews Drug Discovery.

Cytochrome oxidase immunohistochemistry: clues for genetic mechanisms.

J. Cooper, A. Schapira, M. Hanna, 2000, Brain : a journal of neurology.

Targeting mitochondria for neuroprotection in Parkinson disease.

A. Schapira, Sandip Patel, 2014, JAMA neurology.

Polyphenotypic Expression of Mitochondrial Toxicity Caused by Nucleoside Reverse Transcriptase Inhibitors

A. Schapira, I. Weller, M. Hanna, 2002, Antiviral therapy.

Case Report Polyphenotypic expression of mitochondrial toxicity caused by nucleoside reverse transcriptase inhibitors

A. Schapira, I. Weller, M. Hanna, 2003 .

Liver failure associated with mitochondrial DNA depletion.

S. Love, J. Cooper, A. Schapira, 1998, Journal of hepatology.

Congenital muscular dystrophy with severe retrocollis and mental retardation: a report of two siblings.

L. Nashef, A. Schapira, B. Lake, 1997, Journal of neurology, neurosurgery, and psychiatry.

Assessment of the significance of mitochondrial DNA damage by chemotherapeutic agents.

J. Cooper, A. Schapira, D. Hochhauser, 2005, International journal of oncology.

Complex I: Inhibitors, inhibition and neurodegeneration

A. Schapira, 2010, Experimental Neurology.

Glucocerebrosidase and Parkinson disease: Recent advances

A. Schapira, 2015, Molecular and Cellular Neuroscience.

MITOCHONDRIAL COMPLEX I DEFICIENCY IN PARKINSON'S DISEASE

A. H. V. Schapira, J. M. Cooper, D. Dexter, 1989, The Lancet.

Mitochondrial DNA Mutations and Nuclear Mitochondrial Interactions in Human Disease

A. Schapira, J. Taanman, Hannah R Cock, 1999 .

Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death

S. D. de Jager, J. Highley, A. Schapira, 2015, Human molecular genetics.

Brain, skeletal muscle and platelet homogenate mitochondrial function in Parkinson's disease.

C. Marsden, J. Cooper, A. Schapira, 1992, Brain : a journal of neurology.

Molecular mechanisms in mitochondrial DNA depletion syndrome.

J. Cooper, A. Schapira, P. Clayton, 1997, Human molecular genetics.

Respiratory-deficient human fibroblasts exhibiting defective mitochondrial DNA replication.

J. Cooper, A. Schapira, A. Bodnar, 1995, The Biochemical journal.

Nuclear complementation restores mtDNA levels in cultured cells from a patient with mtDNA depletion.

J. Cooper, A. Schapira, A. Bodnar, 1993, American journal of human genetics.

Targeting mitochondria for neuroprotection in Parkinson's disease.

A. Schapira, 2012, Antioxidants & redox signaling.

Antioxidant treatment of patients with Friedreich ataxia: four-year follow-up.

A. Blamire, D. Manners, P. Styles, 2005, Archives of neurology.

Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental lewy body disease

C. Marsden, A. Schapira, D. Dexter, 1992, Annals of neurology.

A missense mutation of cytochrome oxidase subunit II causes defective assembly and myopathy.

I. Nelson, J. Cooper, A. Schapira, 1999, American journal of human genetics.

G2019S leucine-rich repeat kinase 2 causes uncoupling protein-mediated mitochondrial depolarization

M. Duchen, J. Cooper, A. Schapira, 2012, Human molecular genetics.

Possible Mechanisms Underlying the Protective Action of Immunosuppressants Against Parkinson’s Disease

A. Schapira, L. Korlipara, 2002 .

A clinical and genetic study of SPG5A linked autosomal recessive hereditary spastic paraplegia

A. Schapira, N. Wood, T. Warner, 2003, Neurology.

Investigation of somatic CNVs in brains of synucleinopathy cases using targeted SNCA analysis and single cell sequencing

A. Schapira, J. Holton, H. Houlden, 2019, Acta Neuropathologica Communications.

Mitochondrial Dysfunction in Neurodegeneration

J M Cooper, A H Schapira, J. Cooper, 1997, Journal of bioenergetics and biomembranes.

Mitochondrial dysfunction in neurodegeneration: Prospects for neuroprotection

A. Schapira, 1996 .

Complex I Inhibitors Induce Dose‐Dependent Apoptosis in PC12 Cells: Relevance to Parkinson's Disease

A Hartley, A H Schapira, J. Cooper, 1994, Journal of neurochemistry.

Somatic Alpha-Synuclein Mutations in Parkinson's Disease: Hypothesis and Preliminary Data

A. Schapira, H. Houlden, C. Proukakis, 2013, Movement disorders : official journal of the Movement Disorder Society.

Chaperone-mediated autophagy as a therapeutic target for Parkinson disease

A. Schapira, H. Morris, Philip Campbell, 2018, Expert opinion on therapeutic targets.

Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts

K. Lohmann, A. Schapira, A. Ramírez, 2010, PloS one.

Etiology of Parkinson’s disease

Anthony H V Schapira, A. Schapira, 2006, Neurology.

Investigation of Somatic Mutations in Human Brains Targeting Genes Associated With Parkinson's Disease

A. Schapira, A. Schapira, H. Morris, 2020, Frontiers in Neurology.

Recent developments in biomarkers in Parkinson disease

A. Schapira, 2013, Current opinion in neurology.

α-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease

A. Schapira, S. Mullin, 2013, Molecular Neurobiology.

Exploring the Genotype–Phenotype Correlation in GBA-Parkinson Disease: Clinical Aspects, Biomarkers, and Potential Modifiers

A. Schapira, E. Menozzi, 2021, Frontiers in Neurology.

Evolution of prodromal clinical markers of Parkinson disease in a GBA mutation-positive cohort.

A. Schapira, A. McNeill, A. Mehta, 2015, JAMA neurology.

Salbutamol treatment in a patient with hyperkalaemic periodic paralysis due to a mutation in the skeletal muscle sodium channel gene (SCN4A)

N. Wood, A. Schapira, M. Hanna, 1998, Journal of neurology, neurosurgery, and psychiatry.

Clinical, biochemical and molecular genetic correlations in Friedreich's ataxia.

J. Cooper, J. Bradley, A. Schapira, 2000, Human molecular genetics.

Pathogenic LRRK 2 mutations do not alter gene expression in cell model systems or human brain tissue

Michael J. Devine, M. Cookson, J. Hardy, 2017 .

Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue

Michael J. Devine, M. Cookson, J. Hardy, 2011, PloS one.

Neuromyelitis optica (Devic's syndrome): no association with the primary mitochondrial DNA mutations found in Leber hereditary optic neuropathy.

A. Schapira, Hannah R Cock, W. Ahmed, 1997, Journal of neurology, neurosurgery, and psychiatry.

Mitochondrial DNA Mutations and Mitochondrial Dysfunction in Epilepsy

A. Schapira, Hannah R Cock, 1999, Epilepsia.

Biochemical and molecular features of deficiencies of Complexes I, II and III

J. Cooper, A. Schapira, 1994 .

Intronic Haplotypes in the GBA Gene Do Not Predict Age at Diagnosis of Parkinson's Disease

M. Eberle, F. Sedlazeck, A. Schapira, 2021, Movement disorders : official journal of the Movement Disorder Society.

Pramipexole protects against MPTP toxicity in non‐human primates

A. Schapira, J. Cooper, A. Schapira, 2006, Journal of neurochemistry.

A case of recurrent idiopathic ophthalmoplegic neuropathy (Miller Fisher syndrome)

A. Schapira, P. Thomas, 1986, Journal of neurology, neurosurgery, and psychiatry.

Article Title: The Remote Assessment of Parkinsonism Supporting Ongoing Development of Interventions in Gaucher Disease – Study Protocol Short Running Title: The RAPSODI Study

A. Schapira, M. Avenali, S. Koletsi, 2021 .

DNA isolation protocol effects on nuclear DNA analysis by microarrays, droplet digital PCR, and whole genome sequencing, and on mitochondrial DNA copy number estimation

A. Schapira, H. Houlden, Selina Vattathil, 2017, bioRxiv.

Myopathy in vitamin E deficient rats: muscle fibre necrosis associated with disturbances of mitochondrial function.

J. Cooper, A. Schapira, R. King, 1993, Journal of anatomy.

Etiology and pathogenesis of Parkinson disease.

Anthony H V Schapira, A. Schapira, 2009, Neurologic clinics.

Molecular and clinical prodrome of Parkinson disease: implications for treatment

E. Tolosa, A. Schapira, Eduardo Tolosa, 2010, Nature Reviews Neurology.

Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson's disease

W. Poewe, O. Rascol, R. Hauser, 2014, European journal of neurology.

Gene expression in Huntington's disease skeletal muscle: a potential biomarker.

Sarah J Tabrizi, Charles Kooperberg, James M Olson, 2005, Human molecular genetics.

MitBASE : a comprehensive and integrated mitochondrial DNA database. The present status

Domenica D'Elia, Flavio Licciulli, Marcella Attimonelli, 2000, Nucleic Acids Res..

ANO5 Gene Analysis in a Large Cohort of Patients with Anoctaminopathy: Confirmation of Male Prevalence and High Occurrence of the Common Exon 5 Gene Mutation

K. Bushby, F. Muntoni, A. Schapira, 2013, Human mutation.

Chapter 18 - Neuroprotection in Parkinson's Disease

A. Schapira, 2010 .

Neuroprotection in Parkinson's disease.

A. Schapira, 2009, Parkinsonism & related disorders.

Neurobiology and treatment of Parkinson's disease.

Anthony H V Schapira, A. Schapira, 2009, Trends in pharmacological sciences.

Proximal myotonic myopathy (PROMM) presenting as myotonia during pregnancy

G. Meola, A. Schapira, H. Kingston, 1999, Neuromuscular Disorders.

Neurology: Role of the Pharmacist in the Effective Management of Wearing-Off in Parkinson's Disease

R. Hauser, A. Schapira, W. Simonson, 2007, The Annals of pharmacotherapy.

Safinamide for the treatment of Parkinson’s disease

A. Schapira, R. deSouza, 2017, Expert opinion on pharmacotherapy.

Molecular and clinical pathways to neuroprotection of dopaminergic drugs in Parkinson disease

A. Schapira, 2009, Neurology.

Parkinson's disease induced pluripotent stem cells with triplication of the α-synuclein locus

Patrick A. Lewis, Henry Houlden, Nicola J. Drummond, 2011, Nature communications.

Friedreich's ataxia: from disease mechanisms to therapeutic interventions.

R. Lodi, A. Schapira, V. Calabrese, 2006, Antioxidants & redox signaling.

Clinical correlation of brain MRI and MRS abnormalities in patients with Wilson disease

D. MacManus, C. Davie, A. Lees, 2004, Neurology.

British Association for the Study of the Liver

A. Perelson, C. Dejong, Y. Ma, 1991 .

Leber's Hereditary Optic Neuropathy (LHON) Pathogenic Mutations Induce Mitochondrial-dependent Apoptotic Death in Transmitochondrial Cells Incubated with Galactose Medium*

A. Schapira, A. Martinuzzi, A. Porcelli, 2003, The Journal of Biological Chemistry.

Summary of the recommendations of the EFNS/MDS‐ES review on therapeutic management of Parkinson's disease

A. Berardelli, W. Poewe, G. Deuschl, 2013, European journal of neurology.

Timing of Deep Brain Stimulation in Parkinson Disease: A Need for Reappraisal?

Anthony H V Schapira, Elena Moro, A. Lang, 2013, Annals of neurology.

Smoking and mitochondrial function: a model for environmental toxins.

A H Schapira, J. Cooper, A. Schapira, 1993, The Quarterly journal of medicine.

Biochemical and molecular aspects of human mitochondrial respiratory chain disorders.

J. Cooper, A. Schapira, A. Harding, 1990, Biochemical Society transactions.

Nonmotor Symptoms in Experimental Models of Parkinson's Disease.

K. Chaudhuri, A. Schapira, E. Katunina, 2017, International review of neurobiology.

Mitochondrial myopathies: clinical defects.

J. Cooper, A. Schapira, A. Harding, 1990, Biochemical Society transactions.

Cells Bearing Mutations Causing Leber's Hereditary Optic Neuropathy Are Sensitized to Fas-induced Apoptosis*

A. Schapira, G. Cortopassi, A. Martinuzzi, 2002, The Journal of Biological Chemistry.

Isolation of transcriptomal changes attributable to LHON mutations and the cybridization process.

A. Schapira, G. Cortopassi, M. Savontaus, 2005, Brain : a journal of neurology.

Present and future drug treatment for Parkinson’s disease

A H V Schapira, A. Schapira, A. Schapira, 2005, Journal of Neurology, Neurosurgery & Psychiatry.

HLA class II genotypes in Leber's hereditary optic neuropathy

A. Schapira, A. Harding, P. Smith, 1994, Journal of the Neurological Sciences.

Systemic PTEN-Akt1-mTOR pathway activity in patients with normal tension glaucoma and ocular hypertension: A case series.

Haogang Zhu, Anthony H V Schapira, David F Garway-Heath, 2017, Mitochondrion.

Bioenergetic Consequences of PINK1 Mutations in Parkinson Disease

N. Wood, A. Schapira, C. Klein, 2011, PloS one.

Resistance to the most common optic neuropathy is associated with systemic mitochondrial efficiency

I. Gout, A. Schapira, D. Garway-Heath, 2015, Neurobiology of Disease.

Rotigotine transdermal patch in early Parkinson's disease: A randomized, double‐blind, controlled study versus placebo and ropinirole

Nir Giladi, D. Burn, A. Korczyn, 2007, Movement disorders : official journal of the Movement Disorder Society.

The burden of non-motor symptoms in Parkinson's disease using a self-completed non-motor questionnaire: a simple grading system.

K. Chaudhuri, P. Martínez-Martín, A. Schapira, 2015, Parkinsonism & related disorders.

A Proposal for a Comprehensive Grading of Parkinson's Disease Severity Combining Motor and Non-Motor Assessments: Meeting an Unmet Need

David J. Brooks, Angelo Antonini, Pablo Martinez-Martin, 2013, PloS one.

Neurology.

A. Schapira, P. Thomas, P. Sylaja, 1991 .

Friedreich's ataxia: coenzyme Q10 and vitamin E therapy.

J. Cooper, A. Schapira, 2007, Mitochondrion.

Glucocerebrosidase 1 and leucine‐rich repeat kinase 2 in Parkinson disease and interplay between the two genes

A. Schapira, K. Chau, E. Menozzi, 2021, Journal of neurochemistry.

A multinational consensus on dysphagia in Parkinson's disease: screening, diagnosis and prognostic value

E. Tolosa, S. Hamdy, A. Schapira, 2021, Journal of Neurology.

Free radical scavengers protect dopaminergic cell lines from apoptosis induced by complex I inhibitors.

A H Schapira, J. Cooper, A. Schapira, 1997, Brain research.

Disease modification in Parkinson's disease. (vol 3, pg 362, 2004)

A. Schapira, 2004 .

Cardiac energetics are abnormal in Friedreich ataxia patients in the absence of cardiac dysfunction and hypertrophy: an in vivo 31P magnetic resonance spectroscopy study.

A. Blamire, P. Styles, B. Rajagopalan, 2001, Cardiovascular research.

LRRK2 Parkinsonism: Does the Response to Gut Bacteria Mitigate the Neurological Picture?

A. Schapira, A. Schapira, E. Menozzi, 2020, Movement disorders : official journal of the Movement Disorder Society.

Etiopathogenesis and treatment of Parkinson's disease.

A. Schapira, D. Gallagher, 2009, Current topics in medicinal chemistry.

Erratum: A proposal for a comprehensive grading of Parkinson's disease severity combining motor and non-motor assessments: Meeting an unmet need (PLoS ONE (2013) 8: 2 (e57221) DOI: 10.1371/journal.pone.0057221)

David J. Brooks, Angelo Antonini, Kallol Ray Chaudhuri, 2016 .

Normal in vivo skeletal muscle oxidative metabolism in sporadic inclusion body myositis assessed by 31P-magnetic resonance spectroscopy.

A Seller, A H Schapira, S. Tabrizi, 1998, Brain : a journal of neurology.

Metabolic enzyme expression in dopaminergic neurons in Parkinson's disease: An in situ hybridization study

A. Schapira, A. Kingsbury, O. Foster, 2001, Annals of neurology.

Mitochondrial function in neurodegeneration and ageing.

J. Cooper, A. Schapira, A. Schapira, 1992, Mutation research.

Safinamide in the treatment of Parkinson's disease

A. Schapira, 2010, Expert opinion on pharmacotherapy.

Mitochondria in the aetiology and pathogenesis of Parkinson's disease.

A. Schapira, 1999, The Lancet. Neurology.

Drug selection and timing of initiation of treatment in early Parkinson's disease

A. Schapira, C. Olanow, 2008, Annals of neurology.

Genetic and environmental factors in the cause of Parkinson's disease. Discussion

A. Schapira, T. Warner, 2003 .

Efficacy and Safety of Extended- Versus Immediate-Release Pramipexole in Japanese Patients With Advanced and L-dopa–Undertreated Parkinson Disease: A Double-Blind, Randomized Trial

W. Poewe, O. Rascol, R. Hauser, 2012, Clinical neuropharmacology.

Monoamine Oxidase B Inhibitors for the Treatment of Parkinson’s Disease

A. Schapira, 2011, CNS drugs.

Treatment options in the modern management of Parkinson disease.

Anthony H V Schapira, A. Schapira, 2007, Archives of neurology.

First-line Treatment in Parkinson’s Disease

C. Davie, A. Schapira, 2005, Practical Neurology.

Guidelines for the management of Parkinson's disease. The Parkinson's Disease Consensus Working Group.

G. Sawle, D. Brooks, D. Burn, 1998, Hospital medicine.

Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease

V. Visser-Vandewalle, L. Timmermann, K. Lyons, 2020, Journal of Neurology.

PROUD stands tall: delayed-start studies in Parkinson's disease

A. Schapira, 2013 .

International validation of the first united non motor symptoms scale for Parkinson's disease. Results from the first pilot NMSS study

Kallol Ray Chaudhuri, Pablo Martinez-Martin, Anthony H.V. Schapira, 2006 .

MITOCHONDRIAL-FUNCTION IN ALZHEIMERS-DISEASE

J. Cooper, A. Schapira, C. Wischik, 1993 .

HLA class I genotypes in Leber's hereditary optic neuropathy

A. Schapira, A. Harding, R. Chalmers, 1996, Journal of the Neurological Sciences.

Antibodies to human optic nerve in Leber's hereditary optic neuropathy

J. Cooper, A. Schapira, A. Harding, 1995, Journal of the Neurological Sciences.

HLA CLASS-II GENOTYPES IN LEBERS HEREDITARY OPTIC NEUROPATHY

A. Schapira, A. Harding, H. Kellar-Wood, 1994 .

I.P2 Prevalence of non motor symptoms in Parkinson's Disease: An international survey using NMSQuest in 525 patients

K. Chaudhuri, P. Martínez-Martín, U. Bonuccelli, 2006 .

LETTERS TO THE EDITOR

A. Schapira, G. Fénelon, D. D. Di Monte, 1959, Public Health Nutrition.

Updated guidelines for the management of Parkinson's disease.

D. Brooks, D. Burn, A. Schapira, 2001, Hospital medicine.

Mitochondrial DNA analysis in Parkinson's disease

A. Schapira, A. Harding, A. Schapira, 1990, Movement disorders : official journal of the Movement Disorder Society.

Mitochondrial membrane potential, as a measure of mitochondrial function, in patients with normal tension glaucoma vs ocular hypertension

A. Schapira, D. Garway-Heath, Haogang Zhu, 2013 .

Two pregnant women with vomiting and fits.

A. Schapira, J. Rees, L. Ginsberg, 1997, American journal of obstetrics and gynecology.

A mitochondrial encephalomyopathy with specific deficiencies of two respiratory chain polypeptides and a circulating autoantibody to a mitochondrial matrix protein.

J. Cooper, A. Schapira, J. Morgan-Hughes, 1990, Brain : a journal of neurology.

Past, present, and future of Parkinson's disease: A special essay on the 200th Anniversary of the Shaking Palsy

M. Hallett, P. Calabresi, G. Deuschl, 2017, Movement disorders : official journal of the Movement Disorder Society.

Adjunctive ropinirole 24-hour prolonged release compared with adjunctive ropinirole immediate release in patients with advanced PD: results from a per-protocol analysis of the PREPARED study

A. Schapira, F. Stocchi, L. Giorgi, 2008 .

Adjunctive ropinirole 24-hour prolonged release compared with ropinirole immediate release in patients with advanced Parkinson's disease (PD): the PREPARED study

A. Schapira, F. Stocchi, L. Giorgi, 2008 .

On evaluation of symptom control in patients with advanced PD receiving adjunctive ropinirole 24-hour prolonged release versus ropinirole immediate release: results from the PREPARED study

A. Schapira, F. Stocchi, L. Giorgi, 2008 .

Electron transport chain defects in Alzheimer's disease.

H. Reichmann, A. Schapira, H Reichmann, 1994, Neurology.

Neurological effects of glucocerebrosidase gene mutations

A. Schapira, A. Schapira, A. Mehta, 2018, European journal of neurology.

Mitochondrial matters of the brain: the role in Huntington’s disease

A. Schapira, A. Schapira, C. Turner, 2010, Journal of bioenergetics and biomembranes.

Unexpected findings of study of selegiline have not been treated with caution its authors advised

A. Schapira, P. Jenner, Mark T. Silva, 1997, BMJ.

Mitochondrial myopathies: genetic defects.

J. Cooper, A. Schapira, A. Harding, 1990, Biochemical Society transactions.

Mitochondrial disorders.

A. Schapira, 1993, Current Opinion in Genetics and Development.

Parkinson disease: Parkinson disease clinical subtypes and their implications

A. Schrag, A. Schapira, 2011, Nature Reviews Neurology.

P2.159 Efflcacy and safety of once-daily (qd) pramipexole extended-release for advanced Parkinson's disease

W. Poewe, O. Rascol, R. Hauser, 2009 .

P2.155 Simple overnight switching from immediate- to extended-release pramipexole in early Parkinson's disease at the same daily dosage

W. Poewe, O. Rascol, R. Hauser, 2009 .

Future Strategies for Neuroprotection in Parkinson’s Disease

A. Schapira, 2010, Neurodegenerative Diseases.

Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis

A. Schapira, A. Schapira, M. Leinonen, 2009, European journal of neurology.

One-step immunoaffinity purification of complex I subunits from beef heart mitochondria.

J. Cooper, A. Schapira, J. Morgan-Hughes, 1992, Protein expression and purification.

The nondeclaration of nonmotor symptoms of Parkinson's disease to health care professionals: An international study using the nonmotor symptoms questionnaire

K. Chaudhuri, W. Ondo, P. Martínez-Martín, 2010, Movement disorders : official journal of the Movement Disorder Society.

MitBASE: a comprehensive and integrated mitochondrial DNA database

Domenica D'Elia, Marcella Attimonelli, Cecilia Saccone, 1999, Nucleic Acids Res..